Evidence map›Paper›PMID 41478830›Full record

ArticleThe journal of prevention of Alzheimer's disease2026

Plasma Aβ42/40 predicts progression from Aβ-amyloid negative to positive PET scans.

Azadeh Feizpour, Vincent Doré, Pierrick Bourgeat, James D Doecke, Rodrigo Canovas, Simon M Laws, Tenielle Porter, Kun Huang, Christopher Fowler, Ralph N Martins and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of prevention of Alzheimer's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Prognostic value of plasma brain-derived pTau.medRxiv : the preprint server for health sciences · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Azadeh FeizpourFlorey Institute of Neuroscience and Mental Health, The University of Melbourne, 30 Royal Parade, Parkville, VIC, 3052, Australia; Department of Molecular Imaging & Therapy, Austin Health, 145 Studley Road, Heidelberg, VIC, 3084, Australia. Electronic address: azadeh.feizpour@florey.edu.au.
Vincent DoréDepartment of Molecular Imaging & Therapy, Austin Health, 145 Studley Road, Heidelberg, VIC, 3084, Australia; The Australian e-Health Research Centre, CSIRO, 351 Royal Parade, Parkville, VIC, 3052, Australia.
Pierrick BourgeatThe Australian e-Health Research Centre, CSIRO, 296 Herston Rd, Herston, Qld, 4029, Australia.
James D DoeckeThe Australian e-Health Research Centre, CSIRO, 296 Herston Rd, Herston, Qld, 4029, Australia.
Rodrigo CanovasThe Australian e-Health Research Centre, CSIRO, 351 Royal Parade, Parkville, VIC, 3052, Australia.
Simon M LawsCentre for Precision Health, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA, 6027, Australia; Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA, 6027, Australia; Curtin Medical School, Curtin University, Kent Street, Bentley, WA, 6102, Australia.
Tenielle PorterCentre for Precision Health, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA, 6027, Australia; Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA, 6027, Australia; Curtin Medical School, Curtin University, Kent Street, Bentley, WA, 6102, Australia.
Kun HuangDepartment of Molecular Imaging & Therapy, Austin Health, 145 Studley Road, Heidelberg, VIC, 3084, Australia.
Christopher FowlerFlorey Institute of Neuroscience and Mental Health, The University of Melbourne, 30 Royal Parade, Parkville, VIC, 3052, Australia.
Ralph N MartinsAustralian Alzheimer's Research Foundation, Nedlands, WA, 6009, Australia.
Paul MaruffCogstate Ltd, 161 Collins St, Melbourne, VIC, 3000, Australia.
Hamid R SohrabiCentre for Healthy Ageing, Health Futures Institute, Murdoch University, WA, 6150, Australia; School of Psychology, Murdoch University, WA, 6150, Australia.
Michael W WeinerDepartment of Radiology, University of California at San Francisco, San Francisco, 505 Parnassus Avenue, San Francisco, CA, 94143, USA.
John C MorrisDepartment of Neurology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO, 63110, USA; Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight ADRC), Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO, 63110, USA.
Tammie L S BenzingerCharles F. and Joanne Knight Alzheimer Disease Research Center (Knight ADRC), Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO, 63110, USA; Department of Radiology, Washington University in St. Louis, 510 South Kingshighway Boulevard, St. Louis, MO, 63110, USA.
Suzanne E SchindlerDepartment of Neurology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO, 63110, USA; Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight ADRC), Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO, 63110, USA.
Randall J BatemanDepartment of Neurology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO, 63110, USA; Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight ADRC), Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO, 63110, USA; Tracy Family SILQ Center, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO, 63110, USA.
Yan LiDepartment of Neurology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO, 63110, USA.
Ovod VitaliyDepartment of Neurology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO, 63110, USA; Tracy Family SILQ Center, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO, 63110, USA.
Larry WardFlorey Institute of Neuroscience and Mental Health, The University of Melbourne, 30 Royal Parade, Parkville, VIC, 3052, Australia.
Jurgen Mejan-FrippThe Australian e-Health Research Centre, CSIRO, 296 Herston Rd, Herston, Qld, 4029, Australia.
Colin L MastersFlorey Institute of Neuroscience and Mental Health, The University of Melbourne, 30 Royal Parade, Parkville, VIC, 3052, Australia.
Victor L VillemagneDepartment of Psychiatry, University of Pittsburgh, 3811 O'Hara Street, Pittsburgh, PA, 15213, USA.
Christopher C RoweFlorey Institute of Neuroscience and Mental Health, The University of Melbourne, 30 Royal Parade, Parkville, VIC, 3052, Australia; Department of Molecular Imaging & Therapy, Austin Health, 145 Studley Road, Heidelberg, VIC, 3084, Australia. Electronic address: christopher.rowe@austin.org.au.
ADOPIC Consortium (AIBL, ADNI, OASIS)

Funding

Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5M
The natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 2005 to 2025
$49.5M
Research Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI Susan Lynn Stark · 2020 to 2026
$28.7M
Blood amyloid, tau, and neurodegeneration biomarkers and prediction of clinical onset, cognitive decline, and dementia diagnosisR01AG061900 · NIA · WASHINGTON UNIVERSITY · PI RANDALL J BATEMAN · 2024 to 2026
$16.8M
NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P30 AG066444NIA NIH HHS R01 AG061900
6 · The paper itself

Abstract

backgroundThe agreement between plasma Aβ42/40 and Aβ positron emission tomography (PET) is approximately 75 %, with ∼85 % of discrepancies due to positive plasma but negative PET results. It is unclear whether this reflects Aβ changes in plasma before PET-detectable.

objectivesTo assess the influence of Aβ42/40 positivity on risk of progression to Aβ PET positivity, and feasibility of using plasma Aβ42/40 tests to enrich a primary prevention trial.

designA prospective longitudinal cohort study.

settingParticipants of Australian Imaging, Biomarkers and Lifestyle study (AIBL), Alzheimer's Disease Neuroimaging Initiative (ADNI), and Open Access Series of Imaging Studies 3 (OASIS3).

participants507 cognitively unimpaired adults at baseline, with a baseline Aβ PET < 20 Centiloid (CL) and available longitudinal Aβ PET data. MEASUREMENTS: Baseline Aβ PET and plasma Aβ42/40 measurement by mass-spectrometry, followed by 1-6 additional Aβ PET scans every 1.5-3 years. Those < 5 CL were classified as PET- and 5-20 CL as PET

resultsAt baseline, 283 were Plasma-/PET-, 97 Plasma+/PET-, 76 Plasma-/PET

conclusionsCognitively unimpaired individuals with abnormal Aβ42/40 are at increased risk for future Aβ PET positivity. In the 5-20 CL subgroup, baseline CL is the main driver of this risk. Combining blood-based pre-screening with PET imaging may help efficiently enrich primary prevention trials.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesPeptide FragmentsPositron-Emission TomographyAgedBiomarkersBrainDisease ProgressionFemaleHumansLongitudinal StudiesMaleMiddle AgedProspective StudiesAmyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)BiomarkersPeptide FragmentsAlzheimer’s diseaseAβ-amyloid PETPlasma Aβ42/40Primary prevention trialProgression risk

Identifiers

PMID41478830
PMCPMC12869057

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.